n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide has been researched along with Neuritis* in 1 studies
1 other study(ies) available for n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide and Neuritis
| Article | Year |
|---|---|
Anti-allodynic and anti-hyperalgesic effects of nociceptin receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation.
The effects of nociceptin/orphanin FQ (N/OFQ) peptide receptor antagonist JTC-801 on allodynia and hyperalgesia were examined in rats in order to explore the involvement of N/OFQ system in these pathological pain states. Tactile allodynia induced by L5/L6 spinal nerve ligation was reversed by both systemic (3-30 mg/kg) and spinal (22.5 and 45 pg) JTC-801 in a dose-dependent manner. Concerning hyperalgesia induced by formalin injection into the hindpaw, JTC-801 dose-dependently suppressed the second phase, but not the first phase, of the licking behavior. Furthermore, systemic JTC-801 reduced Fos-like immunoreactivity in the dorsal horn of the spinal cord (laminae I/II). In conclusion, N/OFQ receptor antagonist JTC-801 exerted anti-allodynic and anti-hyperalgesic effects in rats, suggesting that N/OFQ system might be involved in the modulation of neuropathic pain and inflammatory hyperalgesia. Topics: Aminoquinolines; Animals; Benzamides; Hyperalgesia; Hyperesthesia; Male; Narcotic Antagonists; Neuritis; Nociceptin Receptor; Pain Measurement; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Spinal Nerves; Touch | 2005 |